Cardiotoxicity of beta-mimetic catecholamines during ontogenetic development - possible risks of antenatal therapy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10377124" target="_blank" >RIV/00216208:11110/18:10377124 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/67985823:_____/18:00492488 RIV/00064165:_____/18:10377124

Výsledek na webu

<a href="https://doi.org/10.1139/cjpp-2017-0774" target="_blank" >https://doi.org/10.1139/cjpp-2017-0774</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1139/cjpp-2017-0774" target="_blank" >10.1139/cjpp-2017-0774</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Cardiotoxicity of beta-mimetic catecholamines during ontogenetic development - possible risks of antenatal therapy

Popis výsledku v původním jazyce

Catecholamines are involved in the regulation of a wide variety of vital functions. The beta-adrenergic receptor (beta-AR) adenylyl cyclase system has been identified early in embryogenesis before the heart has received adrenergic innervation. The structure of beta-receptors in the immature myocardium is similar to that in adults; there are, however, significant quantitative developmental changes in the inotropic and chronotropic responsiveness. Information on the toxic effect of the beta-AR agonists in the immature heart is surprisingly scarce, even though these agents are used in clinical practice both during pregnancy and in early postnatal development. Large doses of beta-AR agonists induce malformations of the cardiovascular system; the type of change depends upon the time at which the beta-AR agonist was administered during embryogenesis. During postnatal ontogeny, the cardiotoxicity of beta-AR agonists increased from birth to adulthood. It seems likely that despite interspecies differences, developmental changes in the cardiac sensitivity to beta-AR agonists may exist in all mammals, depending on the degree of maturation of the system involved in beta-adrenergic signaling. All the existing data draw attention to the possible harmful consequences of the clinical use of beta-AR agonists during early phases of cardiac development. Late effects of the early disturbances of the cardiac muscle cannot be excluded.

Název v anglickém jazyce

Cardiotoxicity of beta-mimetic catecholamines during ontogenetic development - possible risks of antenatal therapy

Popis výsledku anglicky

Catecholamines are involved in the regulation of a wide variety of vital functions. The beta-adrenergic receptor (beta-AR) adenylyl cyclase system has been identified early in embryogenesis before the heart has received adrenergic innervation. The structure of beta-receptors in the immature myocardium is similar to that in adults; there are, however, significant quantitative developmental changes in the inotropic and chronotropic responsiveness. Information on the toxic effect of the beta-AR agonists in the immature heart is surprisingly scarce, even though these agents are used in clinical practice both during pregnancy and in early postnatal development. Large doses of beta-AR agonists induce malformations of the cardiovascular system; the type of change depends upon the time at which the beta-AR agonist was administered during embryogenesis. During postnatal ontogeny, the cardiotoxicity of beta-AR agonists increased from birth to adulthood. It seems likely that despite interspecies differences, developmental changes in the cardiac sensitivity to beta-AR agonists may exist in all mammals, depending on the degree of maturation of the system involved in beta-adrenergic signaling. All the existing data draw attention to the possible harmful consequences of the clinical use of beta-AR agonists during early phases of cardiac development. Late effects of the early disturbances of the cardiac muscle cannot be excluded.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30214 - Obstetrics and gynaecology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Canadian Journal of Physiology and Pharmacology

ISSN

0008-4212

e-ISSN

—

Svazek periodika

96

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

CA - Kanada

Počet stran výsledku

8

Strana od-do

639-646

Kód UT WoS článku

000438114100001

EID výsledku v databázi Scopus

2-s2.0-85049825402